Actavis PLC $197.39

down -1.99


17/4/2014 06:40 PM  |  NYSE : ACT  
Industries : Drugs / Drugs - Generic
Get Trend Analysis Icon Get ACT Trend Analysis - it has outperformed the S&P 500 by 82%

Partner Headlines

  1. IBD 50: Auto, Other IBD 50 Stocks Forming Bases

    IBD
  2. Market Wrap For April 17: Mixed Earnings Drag The Dow Lower While S&P 5 ...

    Benzinga
  3. Actavis to Acquire Four Products from Akorn; Terms Undisclosed

    Benzinga
  4. Market Wrap For April 16: Markets Hold On To Gains An Positive Yellen Comments ...

    Benzinga
  5. Sterne Agee Sees 16% Upside for Actavis, Initiates Coverage

    Benzinga
  6. Benzinga's Top Initiations

    Benzinga
  7. Corporate Cash Kings Escape U.S. Taxes

    FoxBusiness
  8. Facebook, Arris, Grifols Initiate New Bases

    IBD
  9. Market Wrap For April 9: Investors Breathe Sigh Of Relief Over Rate Worries

    Benzinga
  10. Stocks Add To Gains; Intuitive Surgical Slumps On Warning

    IBD
  11. Alexion, Biogen Among Leading Big-Cap Biotechs

    IBD
  12. Stocks Higher In Late Afternoon; First Solar Jumps

    IBD
  13. Stocks Rally, Stall, Turn Mixed; Consol Energy, U.S. Steel Jump

    IBD
  14. Meda Rejects Mylan's Bid

    IBD
  15. Caesarstone, Other Leading Stocks Showing Supporting Action

    IBD
  16. Mylan Bid Gets Rejected, But Generic-Drugmaker Rises

    IBD
  17. Mylan Rejected In Bid To Acquire Sweden's Meda

    IBD
  18. Four Top World Stocks Offer Follow-On Buy Points

    IBD
  19. Actavis

    IBD
  20. Actavis Completes Divestiture of Commercial Operations in Seven Western ...

    Benzinga
  21. Dow Chemical Benefits From 'Flight to Quality' Trade

    IBD
  22. Big Deals Drive Investment Banks, Brokers, Near Highs

    IBD
  23. Stocks On Pace To End Two-Session Slump

    IBD
  24. Selling Pressure Builds In Leading Growth Stocks, Nasdaq

    IBD
  25. Is A Weak-Volume Rebound A No-Go Buy Opportunity?

    IBD
  26. Biotechs, Medicals Get Hurt Amid Price-Inquiry News

    IBD
  27. Gentherm, Kors Setting Up in Tight Formations

    IBD
  28. Horizon Buys Ireland's Vidara

    IBD
  29. Actavis Announces Daytrana Patent Challenge Settlement

    Benzinga
  30. Horizon Pharma To Buy Vidara, Join Exodus To Ireland

    IBD
  31. Should You Buy Actavis?

    GuruFocus
  32. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  33. Market Wrap For March 13: Bears Come Out Of Hibernation As Dow Suffers ...

    Benzinga
  34. Stocks Down 1% In Late Afternoon As Volume Picks Up

    IBD
  35. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  36. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  37. How To Invest: Seek Stock Ideas In Sector Leaders

    IBD
  38. Stock Indexes Reverse Lower, But McDonald's Leaps 3%

    IBD
  39. Highflying Drug, Biotech Stocks Take Rare Drubbing

    IBD
  40. Major Indexes Give Up Early Gains; Jazz, 58.com Rise

    IBD
  41. US Stock Futures Edge Higher; All Eyes On Jobs Report

    Benzinga
  42. Stock Market Closes Mixed; Ambarella Tops Expectations

    IBD
  43. Stock Market Closes Mixed; Medical Leaders Drop

    IBD
  44. Precious Metals, Health Care Led Mutual Funds In Feb.

    IBD
  45. Top Mutual Funds Add To Health Care, Leisure And Banks

    IBD
  46. Drugmakers Actavis, Biogen, Valeant Hold Near Highs

    IBD
  47. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  48. Valeant Beats Q4 Estimates, Talks Buyout Strategy

    IBD
  49. Revenue Growth: Focus On Healthcare Stocks

    YCharts
  50. Gilead Builds Rare Ascending Base

    IBD
Trading Center